Malignant Musculoskeletal Neoplasm

In this 2016 study, the authors analyzed 26 pediatric spindle and sclerosing rhabdomyosarcomas (SRMS) using FISH, targeted DNA, and whole transcriptome sequencing to define their molecular landscape. … (full text at CIViC)

PMID 26501226 · Alaggio et al., 2016 · Open in CIViC

This study looked at 26 spindle cell and sclerosing rhabdomyosarcomas. 11 were congenital/infantile type diagnosed at birth or within one year of age, 10 of which harbored recurrent fusions involving … (full text at CIViC)

PMID 26501226 · Alaggio et al., 2016 · Open in CIViC

In this 2022 study, the authors included 40 patients aged ≤12 months diagnosed with spindle cell rhabdomyosarcoma (SCRMS) enrolled in international trials and registries, of whom 39 presented with loc… (full text at CIViC)

PMID 35452896 · Whittle et al., 2022 · Open in CIViC

In this 2013 study, the authors included 21 spindle cell and sclerosing rhabdomyosarcomas (RMS), and a control group of 4 embryonal RMS and 3 ectomesenchymomas. RNA sequencing and FISH were utilized t… (full text at CIViC)

PMID 23463663 · Mosquera et al., 2013 · Open in CIViC

In this study, the authors investigated the diagnostic role of TFCP2 fusions in spindle cell/sclerosing rhabdomyosarcoma (SC/S-RMS), a rare and aggressive subtype of rhabdomyosarcoma. While SC/S-RMS e… (full text at CIViC)

PMID 31383960 · Le Loarer et al., 2020 · Open in CIViC

This study investigated the role of TFCP2-related gene fusions in primary intraosseous rhabdomyosarcomas (PIOS), particularly within spindle cell and sclerosing rhabdomyosarcoma subtypes. The analysis… (full text at CIViC)

PMID 30720533 · Agaram et al., 2019 · Open in CIViC